Dipeptidyl peptidase-4
Dipeptidyl Peptidase-4 (DPP-4) is an enzyme encoded by the DPP4 gene in humans. DPP-4 plays a significant role in glucose metabolism by inactivating incretin hormones, which are involved in the physiological regulation of glucose homeostasis. Inhibitors of DPP-4 are used in the treatment of Type 2 diabetes because of their ability to increase incretin levels, which inhibit glucagon release, thereby increasing insulin secretion, decreasing gastric emptying, and reducing blood glucose levels.
Function[edit | edit source]
DPP-4 is a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides. Its substrates include incretin hormones such as Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP), which are secreted by intestinal cells in response to meals and enhance insulin secretion from the pancreas. By inactivating these hormones, DPP-4 regulates the effect of incretins on insulin and glucagon secretion.
Clinical Significance[edit | edit source]
The inhibition of DPP-4 has become a therapeutic strategy in the management of Type 2 diabetes, aiming to increase the levels of active incretin hormones, improve beta-cell function, and subsequently improve glycemic control. DPP-4 inhibitors, also known as gliptins, are a class of oral hypoglycemics that block the enzyme's action, thus prolonging the action of incretin hormones.
DPP-4 Inhibitors[edit | edit source]
Several DPP-4 inhibitors have been approved for use, including Sitagliptin, Vildagliptin, Saxagliptin, and Linagliptin. These medications are generally well-tolerated and can be used alone or in combination with other antidiabetic drugs.
Associated Conditions[edit | edit source]
Beyond diabetes, research has explored the role of DPP-4 in various conditions, suggesting its involvement in immune regulation, inflammation, and possibly influencing cardiovascular health. Elevated DPP-4 activity has been observed in various diseases, indicating its potential as a biomarker or therapeutic target beyond diabetes.
Safety and Efficacy[edit | edit source]
DPP-4 inhibitors have been shown to be effective in lowering blood glucose levels with a low risk of hypoglycemia and without causing significant weight gain. However, they are associated with specific adverse effects, such as a risk of pancreatitis and potential joint pain. Ongoing research aims to further elucidate the long-term cardiovascular outcomes associated with their use.
Conclusion[edit | edit source]
DPP-4 and its inhibitors represent a crucial aspect of modern Type 2 diabetes management, with ongoing research into their broader implications for health and disease. As understanding of this enzyme continues to evolve, so too will its therapeutic potential.
Dipeptidyl peptidase-4 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD